These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

273 related items for PubMed ID: 20064077

  • 1. Biopharmaceutical drug targeting to the brain.
    Pardridge WM.
    J Drug Target; 2010 Apr; 18(3):157-67. PubMed ID: 20064077
    [Abstract] [Full Text] [Related]

  • 2. Re-engineering biopharmaceuticals for delivery to brain with molecular Trojan horses.
    Pardridge WM.
    Bioconjug Chem; 2008 Jul; 19(7):1327-38. PubMed ID: 18547095
    [Abstract] [Full Text] [Related]

  • 3. Reengineering biopharmaceuticals for targeted delivery across the blood-brain barrier.
    Pardridge WM, Boado RJ.
    Methods Enzymol; 2012 Jul; 503():269-92. PubMed ID: 22230573
    [Abstract] [Full Text] [Related]

  • 4. Genetic engineering, expression, and activity of a fusion protein of a human neurotrophin and a molecular Trojan horse for delivery across the human blood-brain barrier.
    Boado RJ, Zhang Y, Zhang Y, Pardridge WM.
    Biotechnol Bioeng; 2007 Aug 15; 97(6):1376-86. PubMed ID: 17286273
    [Abstract] [Full Text] [Related]

  • 5. Drug targeting of erythropoietin across the primate blood-brain barrier with an IgG molecular Trojan horse.
    Boado RJ, Hui EK, Lu JZ, Pardridge WM.
    J Pharmacol Exp Ther; 2010 Jun 15; 333(3):961-9. PubMed ID: 20233799
    [Abstract] [Full Text] [Related]

  • 6. Molecular Trojan horses for blood-brain barrier drug delivery.
    Pardridge WM.
    Curr Opin Pharmacol; 2006 Oct 15; 6(5):494-500. PubMed ID: 16839816
    [Abstract] [Full Text] [Related]

  • 7. Genetic engineering of a lysosomal enzyme fusion protein for targeted delivery across the human blood-brain barrier.
    Boado RJ, Zhang Y, Zhang Y, Xia CF, Wang Y, Pardridge WM.
    Biotechnol Bioeng; 2008 Feb 01; 99(2):475-84. PubMed ID: 17680664
    [Abstract] [Full Text] [Related]

  • 8. Genetic engineering of a bifunctional IgG fusion protein with iduronate-2-sulfatase.
    Lu JZ, Hui EK, Boado RJ, Pardridge WM.
    Bioconjug Chem; 2010 Jan 01; 21(1):151-6. PubMed ID: 20000684
    [Abstract] [Full Text] [Related]

  • 9. A new generation of neurobiological drugs engineered to overcome the challenges of brain drug delivery.
    Boado RJ.
    Drug News Perspect; 2008 Nov 01; 21(9):489-503. PubMed ID: 19180267
    [Abstract] [Full Text] [Related]

  • 10. Humanization of anti-human insulin receptor antibody for drug targeting across the human blood-brain barrier.
    Boado RJ, Zhang Y, Zhang Y, Pardridge WM.
    Biotechnol Bioeng; 2007 Feb 01; 96(2):381-91. PubMed ID: 16937408
    [Abstract] [Full Text] [Related]

  • 11. Selective plasma pharmacokinetics and brain uptake in the mouse of enzyme fusion proteins derived from species-specific receptor-targeted antibodies.
    Zhou QH, Boado RJ, Pardridge WM.
    J Drug Target; 2012 Sep 01; 20(8):715-9. PubMed ID: 22845843
    [Abstract] [Full Text] [Related]

  • 12. Tumor necrosis factor receptor-IgG fusion protein for targeted drug delivery across the human blood-brain barrier.
    Hui EK, Boado RJ, Pardridge WM.
    Mol Pharm; 2009 Sep 01; 6(5):1536-43. PubMed ID: 19624167
    [Abstract] [Full Text] [Related]

  • 13. GDNF fusion protein for targeted-drug delivery across the human blood-brain barrier.
    Boado RJ, Zhang Y, Zhang Y, Wang Y, Pardridge WM.
    Biotechnol Bioeng; 2008 Jun 01; 100(2):387-96. PubMed ID: 18080333
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Drug targeting to the brain.
    Pardridge WM.
    Pharm Res; 2007 Sep 01; 24(9):1733-44. PubMed ID: 17554607
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Molecular Trojan horses for blood-brain barrier drug delivery.
    Pardridge WM.
    Discov Med; 2006 Aug 01; 6(34):139-43. PubMed ID: 17234133
    [Abstract] [Full Text] [Related]

  • 18. Targeted delivery of protein and gene medicines through the blood-brain barrier.
    Pardridge WM.
    Clin Pharmacol Ther; 2015 Apr 01; 97(4):347-61. PubMed ID: 25669455
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Blood-brain barrier delivery.
    Pardridge WM.
    Drug Discov Today; 2007 Jan 01; 12(1-2):54-61. PubMed ID: 17198973
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.